Medicis Pharmaceutical Corporation
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 8 name spellings.
17
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 7 to 14, 2027 · next Jan 7
- 1 fee due Mar 12, 2027The maintenance fee for Anti-Inflammatory, Anti-Cancer, and Anti-Angiogenic Compounds, Pharmaceutical Compositions, and Methods of Making and Using Thereof (US 11,752,146) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Sustained Release Drug Delivery Systems with Reduced Impurities and Related Methods (US 11,771,624) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Method for the Treatment of Acne and Certain Dosage Forms Thereof (US 9,192,615) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Genital and Perianal Warts (US 11,850,245) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,483 | Method for the Treatment of Acne In force · Medium confidence | In force | Medium confidence | |
| US 7,541,347 | Minocycline Oral Dosage Forms for the Treatment of Acne In force · Medium confidence | In force | Medium confidence | |
| US 7,544,373 | Minocycline Oral Dosage Forms for the Treatment of Acne In force · Medium confidence | In force | Medium confidence | |
| US 11,202,752 | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis with Shorter Durations of Imiquimod Therapy In force · Low confidence | In force | Low confidence | |
| US 8,222,270 | 2 X 2 X 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod In force · Low confidence | In force | Low confidence | |
| US 8,236,816 | 2 X 2 X 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75 % Imiquimod In force · Low confidence | In force | Low confidence | |
| US 8,299,109 | Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream In force · Low confidence | In force | Low confidence | |
| US 11,318,130 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD In force · Low confidence | In force | Low confidence | |
| US 10,028,957 | Depot Formulations In force · Medium confidence | In force | Medium confidence | |
| US 9,078,889 | Lower Dosage Strength Imiquimod Formulations and Short Dosing Regimens for Treating Genital and Perianal Warts In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 41: 15 patents in force now held by others · 67 lapsed for an unpaid fee · 64 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 19 abandoned · 17 no status recorded